BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24533814)

  • 1. Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review.
    Zhuang C; Miao Z; Sheng C; Zhang W
    Curr Med Chem; 2014; 21(16):1861-70. PubMed ID: 24533814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
    Taguchi K; Motohashi H; Yamamoto M
    Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
    Marcotte D; Zeng W; Hus JC; McKenzie A; Hession C; Jin P; Bergeron C; Lugovskoy A; Enyedy I; Cuervo H; Wang D; Atmanene C; Roecklin D; Vecchi M; Vivat V; Kraemer J; Winkler D; Hong V; Chao J; Lukashev M; Silvian L
    Bioorg Med Chem; 2013 Jul; 21(14):4011-9. PubMed ID: 23647822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
    Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
    J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
    Pallesen JS; Tran KT; Bach A
    J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
    Uruno A; Motohashi H
    Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
    Jiang ZY; Lu MC; You QD
    J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
    Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
    Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
    Abed DA; Goldstein M; Albanyan H; Jin H; Hu L
    Acta Pharm Sin B; 2015 Jul; 5(4):285-99. PubMed ID: 26579458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents.
    Magesh S; Chen Y; Hu L
    Med Res Rev; 2012 Jul; 32(4):687-726. PubMed ID: 22549716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
    Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
    Jiang ZY; Lu MC; Xu LL; Yang TT; Xi MY; Xu XL; Guo XK; Zhang XJ; You QD; Sun HP
    J Med Chem; 2014 Mar; 57(6):2736-45. PubMed ID: 24512214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response.
    Tong KI; Padmanabhan B; Kobayashi A; Shang C; Hirotsu Y; Yokoyama S; Yamamoto M
    Mol Cell Biol; 2007 Nov; 27(21):7511-21. PubMed ID: 17785452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.
    Inoyama D; Chen Y; Huang X; Beamer LJ; Kong AN; Hu L
    J Biomol Screen; 2012 Apr; 17(4):435-47. PubMed ID: 22156223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.
    Georgakopoulos N; Talapatra S; Dikovskaya D; Dayalan Naidu S; Higgins M; Gatliff J; Ayhan A; Nikoloudaki R; Schaap M; Valko K; Javid F; Dinkova-Kostova AT; Kozielski F; Wells G
    J Med Chem; 2022 May; 65(10):7380-7398. PubMed ID: 35549469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an enzyme-linked immunosorbent assay for Keap1-Nrf2 interaction inhibitors identification.
    Wang Y; Xiao CY; Lin HQ; Hu JS; Ip TM; Chi-Cheong Wan D
    Redox Biol; 2020 Jul; 34():101573. PubMed ID: 32422542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.